Safety and efficacy of gout treatments in people with renal impairment-Reference-Cited by-同舟云学术

Safety and efficacy of gout treatments in people with renal impairment

Published:2024-09-02 Issue:5 Volume:2 Page:360-374
ISSN:
Container-title:Exploration of Musculoskeletal Diseases
language:en
Short-container-title:Explor Musculoskeletal Dis

Author:

Farquhar Hamish¹^ORCID,Gaffo Angelo²^ORCID,Stamp Lisa K.¹^ORCID

Affiliation:

1. Department of Rheumatology, Immunology and Allergy, Health New Zealand, Christchurch 8011, New Zealand; Department of Medicine, University of Otago Christchurch, Christchurch 8011, New Zealand

2. Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL 35294, USA; Birmingham VA Medical Center, Birmingham, AL 35233, USA

Abstract

Gout is common in people with chronic kidney disease and in general is sub-optimally managed. Lack of evidence due to the exclusion of people with chronic kidney disease from the majority of clinical trials, concerns about adverse effects and conflicting gout management guidelines all contribute to suboptimal management. Herein we review the evidence for the pharmacological treatment of gout, both flares and long-term urate-lowering, in people with concomitant chronic kidney disease.

Publisher

Open Exploration Publishing

Reference88 articles.

1. Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17:633–41. [PMID: 34331037 PMCID: PMC8458096 DOI: 10.1038/s41584-021-00657-4]

2. Jaffe DH, Klein AB, Benis A, Flores NM, Gabay H, Morlock R, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019;3:11. [PMID: 30937425 PMCID: PMC6425669 DOI: 10.1186/s41927-019-0060-0]

3. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7:e50046. [PMID: 23209642 PMCID: PMC3507834 DOI: 10.1371/journal.pone.0050046]

4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679–87.e1. [PMID: 22626509 DOI: 10.1016/j.amjmed.2011.09.033]

5. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90. [PMID: 25889144 PMCID: PMC4404569 DOI: 10.1186/s13075-015-0610-9]